By Samuel Indyk
Investing.com – Novacyt (LON:NCYT) Chief Executive Graham Mullis has announced he is to retire, standing down as CEO and board member. David Allmond has been appointed as Mullis’ replacement, effective from 18th October 2021.
Allmond is currently Chief Business Officer at dual-listed Amryt Pharma (LON:AMYT), where he has helped the company in its development into a global rare and orphan disease drug company. Previously, Allmond has worked in sales and marketing roles at large pharmaceutical companies, including Amgen (NASDAQ:AMGN), Celgene and Aegerion.
“I am excited to be joining Novacyt at a pivotal phase in its development and I am looking forward to building upon Graham's outstanding work with the business over the past 13 years,” Allmond said in a statement. “Novacyt is poised for its next phase of growth and I am confident I can lead the Company effectively through this period, working closely with the excellent management team and Board to make a significant contribution to global health and deliver sustained and ongoing value to our shareholders.”
Speaking on the appointment, Novacyt Chairman James Wakefield said: “The Board is highly confident that, after an extensive search, we have found the right leader for Novacyt's next chapter of growth, following Graham's decision to retire.”
“He [Graham Mullis] leaves a legacy of having created one of the UK's leading diagnostic businesses and should be proud of the role the Company has played, and continues to play, in supporting nations and businesses in their response to the COVID-19 pandemic.”
At 10:24BST, shares in Novacyt were trading lower by 0.5% at 329.22 pence per share.